A
Description
Swedish clinical-stage biotech founded in 1998 (Lund University), specialised in fibrosis and joint diseases. Develops AM1476, a first-in-class oral 5-HT2B antagonist for systemic sclerosis (skin and lung). SEK 75M financing in 2024.